Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS: Because of the risk of severe encephalopathy, we conclude that patients who have previously received cisplatin or who receive ifosfamide at doses >or=9 g/m(2) require strict monitoring.
|
Authors | Takahiro Tajino, Shin-ichi Kikuchi, Hitoshi Yamada, Akira Takeda, Shin-ichi Konno |
Journal | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
(J Orthop Sci)
Vol. 15
Issue 1
Pg. 104-11
(Jan 2010)
ISSN: 1436-2023 [Electronic] Japan |
PMID | 20151259
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Cisplatin
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Bone Neoplasms
(drug therapy)
- Child
- Cisplatin
(adverse effects)
- Dose-Response Relationship, Drug
- Drug Synergism
- Female
- Humans
- Ifosfamide
(administration & dosage, adverse effects)
- Incidence
- Japan
(epidemiology)
- Male
- Middle Aged
- Muscle Neoplasms
(drug therapy)
- Neurotoxicity Syndromes
(epidemiology, etiology)
- Retrospective Studies
- Risk Factors
- Sarcoma
(drug therapy)
- Young Adult
|